期刊文献+

MTHFR C677T位点,ABCG2 G34A位点基因型与Ⅳ期结肠腺癌无进展生存期的关系 被引量:2

Association of single nucleotide polymorphisms of MTHFR C677T and ABCG2 G34A with progression-free survival of stage Ⅳ colon adenocarcinoma
下载PDF
导出
摘要 目的 分析亚甲基四氢叶酸还原酶(MTHFR)、三磷酸腺苷结合转运蛋白G超家族第2成员(ABCG2)基因单核苷酸多态性(SNP)与Ⅳ期结肠腺癌预后的关系。方法对2011年1月至2015年1月收治的137例Ⅳ期结肠腺癌患者进行回顾性分析。检测患者外周血MTHFR C677T位点,ABCG2 G34A位点的SNP,随访统计患者无进展生存期(PFS)。分析MTHFR、ABCG2的SNP与患者预后的关系。结果 MTHFR C677T位点野生型42例,突变型95例;ABCG2 G34A位点野生型63例,突变型74例。单独分析显示上述位点突变与患者PFS无明显关系;综合分析中,以MTHFR C677T位点野生型和ABCG2 G34A突变型为优势基因型,具备2个优势基因型的患者中位PFS明显长于具备0~1个优势型患者,差异有统计学意义( P <0.05)。Cox回归分析显示优势基因型个数不是患者PFS的独立影响因素( P >0.05)。结论 MTHFR、ABCG2的SNP与Ⅳ期结肠腺癌预后有一定关系,但具备优势基因型并不是患者预后的独立影响因素。 Objective To analyze the relationship between single nucleotide polymorphism (SNP) of methylenetetrahydrofolate reductase (MTHFR),ATP-binding cassette sub-family G member 2 (ABCG2) gene and prognosis of stage IV colon adenocarcinoma.Methods From January 2011 to January 2015,137 patients with stage IV colon adenocarcinoma were analyzed retrospectively. The SNPs of MTHFR C677 T and ABCG2 G34A in peripheral blood were detected,and PFS was followed up,the relationship between the SNPs of MTHFR and ABCG2 and the prognosis of patients were analyzed. Results accounted for 42 cases,with mutant type accounted for 95 cases. Patients with wild type of ABCG2 G34A accounted for 63 cases,with mutant type accounted for 74 cases. Individual analysis showed that there was no significant relationship between the above mutations and PFS. In comprehensive analysis,the dominant genotypes were MTHFR C677 T wild type and ABCG2 G34A mutations. The median PFS of patients with 2 dominant genotypes was significantly longer than that of patients with 0-1 dominant genotype (P < 0. 05). Cox regression analysis showed that the number of dominant genotypes was not an independent factor of PFS (P > 0. 05). Conclusion SNPs of MTHFR and ABCG2 is related to the prognosis of stage IV colon adenocarcinoma,but the dominant genotype is not an independent factor affecting the prognosis of patients.
作者 张卫华 代婀娜 何源雄 ZHANG Wei-hu;DAI E-na;HE Yuan-xiong(Hospital Affiliated to Shandong Academy of Medical Sciences,Internal Five Departments,250031;Hospital Affiliated to Shandong Academy of Medical Sciences,Surgical Three Departments,250031)
出处 《现代消化及介入诊疗》 2019年第7期751-754,共4页 Modern Interventional Diagnosis and Treatment in Gastroenterology
关键词 结肠腺癌 亚甲基四氢叶酸还原酶 三磷酸腺苷结合转运蛋白G超家族第2成员 单核苷酸多态性 Colon adenocarcinoma Methylenetetrahydrofolate reductase ATP-binding cassette sub-family G member 2 Single nucleotide polymorphism
  • 相关文献

参考文献7

二级参考文献69

  • 1张弘纲,李进,秦叔逵,张燕军,宋恕平,储大同.国产伊立替康加5-氟尿嘧啶加亚叶酸钙联合沙利度胺治疗晚期大肠癌的随机对照研究[J].中华肿瘤杂志,2007,29(3):228-231. 被引量:16
  • 2JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J CUn, 201 1, 61(2):69-90. 被引量:1
  • 3TOURNIGAND C, ANDRE T, ACHILLE E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized CERCOR study[J].JClin Oncol, 2004, 22(2):229-237. 被引量:1
  • 4COLUCCI G, GEBBIA V, PAOLETTI G,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Cruppo Oncologico Dell,Italia Meridionale[J].J Clin Oncol, 2005, 23(22):4866-4875. 被引量:1
  • 5DUCREUX M, BENNOUNA J, HEBBAR M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128(3):682-690. 被引量:1
  • 6ENCSTROM P F, ARNOLETTI J P,BENSON A R, et aL NCCN Clinical Practice Guidelines in Oncology: colon cancer[J]. J Natl Compr Cane Neter 2009, 7(8):778-831. 被引量:1
  • 7Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. AdvancedColorectal Cancer Meta-Analysis Project[J].J ClinOncol, 1992, 10(6):896-903. 被引量:1
  • 8VAN CUTSEM E, HOFF P M,HARPER P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials[J].BrJ Cancer, 2004, 90(6):11 90-1197. 被引量:1
  • 9HOFF P M,ANSARI R,BATIST G, ef al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study[J].J Clin Oncol, 2001,19(8):2282-2292. 被引量:1
  • 10DOROSHOW J H, MULTHAUF P, LEONG L,et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy[J]. J Clin Oncol, 1 990, 8(3):491-501. 被引量:1

共引文献130

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部